Home

NeOnc Technologies Holdings, Inc. - Common Stock (NTHI)

5.0015
-0.9485 (-15.94%)
NASDAQ · Last Trade: Jul 10th, 11:16 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
NeOnc Technologies Secures Board Approval for $50 Million Strategic Partnership with Quazar Investment
CALABASAS, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, today announced it has achieved a key milestone toward closing its previously announced strategic transaction with Quazar Investment: formal approval from NeOnc’s Board of Directors.
NeOnc Technologies Holdings, Inc. Joins Russell Microcap® Index
CALABASSAS, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders, has joined the Russell Microcap® Index following the conclusion of the 2025 Russell indexes annual reconstitution.
NeOnc Technologies Signs $50 Million Non-Binding Strategic Term Sheet with Quazar Investment to Launch GCC & MENA Expansion and Clinical Trials Platform
CALABASAS, Calif., July 08, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, today announced it has signed a non-binding term sheet with Quazar Investment to form a new UAE-based investment and clinical platform focused on the Middle East and North Africa (MENA) region.
NeOnc Technologies Holdings, Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to Advance Clinical Strategy and Translational Oncology Programs
USC brain tumor authority to accelerate four clinical trials including lead asset NEO100 nearing Phase 2a completion ahead of schedule
NeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical Markets
-- 176 Patents Issued and Outstanding Reinforces NeOnc’s Competitive Position --
NeOnc Technologies Holdings, Inc. Expects Full Enrollment in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas in September
-- Trial Read-Out Data Expected in Early 2026 --
NeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company’s New President
CALABASAS, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders, today announced that Executive Chairman Amir Heshmatpour has been appointed to serve as President of the Company. Heshmatpour will retain his role as Executive Chairman, while taking on day-to-day leadership responsibilities to accelerate the Company’s strategic and clinical initiatives.
NeOnc Technologies Announces Near Completion of Phase I Enrollment for NEO212 Brain Cancer Therapy
CALABASAS, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders, today announced that its Phase I clinical trial of NEO212, a development-stage bio-conjugated therapeutic for brain cancer, is nearing full enrollment. The final cohort (Cohort 5) is expected to complete the study’s dosing protocol, marking a major milestone in the drug’s development timeline.
NeOnc Technologies Holdings, Inc. Receives Rare Pediatric Disease Designation for NEO100 in Treatment of Pediatric-Type Diffuse High-Grade Gliomas
WESTLAKE VILLAGE, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ Global Market: NTHI), a clinical-stage medical biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to perillyl alcohol (NEO100™) for the treatment of pediatric-type diffuse high-grade gliomas, a serious and life-threatening condition affecting children and adolescents.
NeOnc Technologies Expands Global Clinical Trial Network with CBCC Global Research to Accelerate Study of Brain Cancer Treatments
WESTLAKE VILLAGE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq Global Market: NTHI), a clinical-stage medical biotechnology company, today announced a strategic partnership with CBCC Global Research (CBCC), a premier full-service clinical research organization (CRO). This collaboration will expand NeOnc’s clinical trial capabilities in India, facilitating the advancement of its development-stage neuro-oncology treatment.